[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-microbiota\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-microbiota":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,78,124,161,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100637561","hyaluronic-acid-as-an-adjunct-to-non-surgical-periodontal-therapy-in-smokers-100637561",false,"NCT07597213","Hyaluronic Acid as an Adjunct to Non-Surgical Periodontal Therapy in Smokers","The Effect of Adjunctive Use of Hyaluronic Acid in Non-Surgical Periodontal Treatment in Smoking Patients","Inclusion Criteria:\n\n1. Individuals who sign the informed consent form\n2. Participants who are systemically healthy\n3. Participants who smoke (for \\>5 years and ≥10 cigarettes per day)\n4. Participants diagnosed with Stage III or Stage IV periodontitis\n5. Participants with at least 20 natural teeth present in the mouth (excluding third molars)\n6. Participants with two non-adjacent interproximal sites in each quadrant of either jaw, presenting probing depth (PD) and clinical attachment level (CAL) ≥6 mm, and with no caries, restorations, or furcation involvement\n\nExclusion Criteria:\n\n1. Individuals who do not sign the informed consent form\n2. Individuals having any systemic disease\n3. Participants who have used antibiotics within the last 3 months\n4. Participants who have received any periodontal treatment within 6 months prior to the study\n5. Participants who are pregnant or lactating","ALL","18 Years","65 Years",{"count":20,"type":21},23,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether hyaluronic acid (HA) improves periodontal healing in people with periodontal disease who smoke. Moreover, the effects of HA on biomolecules and bacteria levels will be assessed during the follow up period.\n\nThe main questions it will answer are:\n\nWill periodontal sites treated with HA gel after non-surgical periodontal treatment (NSPT) lead to better outcomes in clinical parameters compared to the sites treated with NSPT only in smokers?\n\nWill adjunctive use of HA gel reduce oxidative stress markers and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* first receive full-mouth NSPT then, randomization will be performed in selected jaw to determine the test sites. These two interproximal test sites will additionally receive HA gel application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for Metallothionein (MT) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and subgingival samples for periodontal pathogens.",[27,28,29,30,31,32,33],"Hyaluronic Acid","Periodontal Therapy","Oral Microbiota","Oxidative Stress","Metallothionein","8-OHdG","Periodontitis",[35,36,37,38,32,39,40],"hyaluronic acid","periodontitis","periodontal pathogens","metallothionein","Non-surgical periodontal treatment","split-mouth study","NOT_YET_RECRUITING","2026-06-03",{"date":44,"type":45},"2026-06-05","ACTUAL",{"date":47,"type":21},"2026-06",{"date":49,"type":21},"2028-07",{"name":51,"class":52},"Marmara University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":77,"locationsCount":53},"100643782","adjunctive-hyaluronic-acid-gel-in-non-surgical-periodontal-treatment-of-patients-with-diabetes-mellitus-100643782","NCT07631273","Adjunctive Hyaluronic Acid Gel in Non-Surgical Periodontal Treatment of Patients With Diabetes Mellitus","The Effect of Hyaluronic Acid on Non-Surgical Periodontal Treatment in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Individuals who sign the informed consent form\n* Participants diagnosed with diabetes mellitus (HbA1c %7-7.9)\n* Participants without any systemic disease other than DM\n* Participants diagnosed with Stage III or Stage IV periodontitis\n* Nonsmokers\n* Participants with at least 15 natural teeth present in the mouth (excluding third molars)\n* Participants in either of the jaws, in both quadrants, having two non-adjacent interproximal sites with probing depth and clinical attachment level ≥6 mm with no caries, restorations or furcation involvement\n\nExclusion Criteria:\n\n* Individuals who do not sign the informed consent form\n* Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis\n* Participants have received any periodontal treatment within 6 months prior to the study\n* Participants who have used antibiotics within the last 3 months\n* Smokers\n* Participants who are pregnant or lactating",{"count":20,"type":21},[24],"The goal of this clinical trial is to evaluate whether the adjunctive use of hyaluronic acid (HA) improves periodontal healing in people with diabetes mellitus and periodontitis. The effects of HA on biomolecules and bacteria levels will be assessed during the follow-up period.\n\nThe main questions the study will answer are:\n\n* Will periodontal sites treated with non-surgical periodontal treatment (NSPT) plus HA gel show better clinical periodontal parameters than sites treated with only NSPT in patients with diabetes and periodontitis?\n* will HA gel have additional effect on reducing inflammation or collagen markers, and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* provide recent HbA1c test results.\n* then, the participants will receive full-mouth NSPT then, randomization will be performed for the selected jaw for test sites. These two interproximal test sites will additionally receive HA application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for interleukin-34 (IL-34) and beta C-terminal telopeptide (β-CTX) levels and subgingival samples for periodontal pathogens.",[33,65,27,29,66,67],"Diabetes Mellitus","IL-34","β-CTX",[33,69,70,27,71,66,67,37],"diabetes mellitus","Non-surgical Periodontal Treatment","Split-mouth Study","2026-06-02",{"date":74,"type":45},"2026-06-08",{"date":47,"type":21},{"date":49,"type":21},{"name":51,"class":52},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":105,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":53},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594","NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.",true,"56 Years","74 Years",{"count":90,"type":21},1400,"OBSERVATIONAL","The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[94,95,96,97,98,99,100,101,102,29,103,104],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Pulmonary Disease, Chronic Obstructive (COPD)","Steatohepatitis","Inflammation Biomarkers","Lipid Profile","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[106,107,108,109,110,111,112,113],"coronary artery disease","arterial stiffness","MASLD","COPD","inflammation","dyslipidemia","aortic aneurysm","oral microbiota","RECRUITING","2026-03-12",{"date":117,"type":45},"2026-03-17",{"date":119,"type":45},"2024-04-08",{"date":121,"type":21},"2026-08-30",{"name":123,"class":52},"Danderyd Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":132,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":53},"100598257","lactoferrin-based-oral-care-for-periodontal-health-in-pregnancy-100598257","NCT07069140","Lactoferrin-Based Oral Care for Periodontal Health in Pregnancy","Effectiveness of an Oral Care Protocol Based on Lactoferrin Toothpaste and Mouthwash in Pregnant Women for the Prevention of Periodontal Disease: A Randomized Controlled Clinical Trial","LBC-PREG","Inclusion Criteria:\n\n* Pregnant women aged between 18 and 45 years\n* Gestational age between 14 and 28 weeks at the time of enrollment (second trimester)\n* Diagnosis of periodontitis according to the 2017 World Workshop classification (Stages I-III, Grades A-B)\n* Presence of at least 20 natural teeth\n* Willingness to comply with study procedures and attend follow-up visits\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of systemic diseases that could affect periodontal status (e.g., diabetes mellitus, immunosuppression)\n* Antibiotic or anti-inflammatory therapy within 3 months prior to enrollment Current use of probiotics, antioxidant supplements, or medicated mouthwashes\n* Periodontal treatment within 6 months before enrollment\n* High-risk pregnancy or pregnancy complications (e.g., preeclampsia, gestational diabetes)\n* Smoking or tobacco use\n* Known allergy to any of the investigational product components\n* Participation in another clinical trial within the previous 3 months","FEMALE","45 Years",{"count":135,"type":21},40,[24],"This randomized controlled clinical trial aims to evaluate the effectiveness of a lactoferrin-based oral hygiene protocol in improving periodontal health during pregnancy. Forty pregnant women between the fourth and eighth month of gestation will be enrolled and randomly assigned to one of two groups. The trial group will undergo professional dental cleaning every three months and will perform home oral hygiene using both a lactoferrin-based toothpaste and a lactoferrin-based mouthwash (Emoform Glic) twice daily. The control group will follow the same schedule of professional dental cleanings but will use only the lactoferrin-based toothpaste (Emoform Glic) at home. The primary objective is to assess the reduction in dental plaque, measured by the Plaque Index (PI). Secondary outcomes include improvements in gingival inflammation, probing pocket depth, clinical attachment level, and other periodontal indices. Participants will be followed for six months, with evaluations conducted at baseline, 1, 3, and 6 months.",[139,140,141,29],"Pregnancy","Periodontal Disease","Gingivitis",[143,139,140,29,144,141,145,146,147,148,149,150,151],"Lactoferrin","Dental Plaque","Non-surgical Periodontal Therapy","Toothpaste","Mouthwash","LBC Complex","Maternal Oral Health","Randomized Controlled Trial","Oral Hygiene in Pregnancy","2026-02-19",{"date":154,"type":45},"2026-02-20",{"date":156,"type":45},"2025-07-30",{"date":158,"type":21},"2026-06-10",{"name":160,"class":52},"University of Pavia",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":86,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":53},"100594141","the-characteristics-of-oral-microbiota-in-chronic-pancreatitis-and-autoimmune-pancreatitis-100594141","NCT07015580","The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis","Inclusion Criteria:\n\n* A dated and signed informed consent form cooperate to complete sample collection\n\nExclusion Criteria:\n\n* Previous digestive system surgery; During pregnancy or lactation; Complicated with infectious diseases, malignant tumors or other digestive system diseases (such as inflammatory bowel disease, irritable bowel syndrome, abdominal diseases, gastroesophageal reflux, etc.); Antibiotics and immunosuppressive drugs were used within 30 days before sampling; Those who take probiotics daily.",{"count":168,"type":21},360,"There are more than 700 different bacteria colonized in human oral cavity, which are collectively referred to as oral microbiota. Emerging evidence suggests that oral microbiota plays a series of important roles in human health, such as immune response, carcinogen metabolism and nutrient digestion. The changes of oral microbiota composition are closely related to the occurrence and development of pancreatic diseases. Previous studies have found that there are dense bacterial biofilms in the pancreatic duct of patients with calcified pancreatitis, including oral bacterial types. However, most studies only focused on the changes of gut microbiota in patients with chronic pancreatitis, and there were lack of research and description on the changes of oral microbiota in patients with chronic pancreatitis. In this study, we will extract and sequence bacterie's full-length 16S rRNA to describe the characteristics of oral microbiota in patients with chronic pancreatitis, confirming that there are changes in oral microbiota in patients with chronic pancreatitis, and compare the differences of oral microbiota in patients with chronic pancreatitis, pancreatic cancer and autoimmune pancreatitis.",[29,171,172],"Pancreatitis","Pancreatic Cancer","2025-06-04",{"date":175,"type":45},"2025-06-11",{"date":177,"type":45},"2025-02-18",{"date":179,"type":21},"2026-02-28",{"name":181,"class":52},"Ruijin Hospital",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":188,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":53},"100511727","clinical-and-microbiological-approach-in-orthopedic-treatment-of-patients-when-choosing-a-structural-material-100511727","NCT05943197","Clinical and Microbiological Approach in Orthopedic Treatment of Patients When Choosing a Structural Material","Inclusion Criteria:\n\n\\- need for prosthetics\n\nExclusion Criteria:\n\n\\- lack of indications for treatment","1 Month",{"count":190,"type":21},80,[24],"Today, there is a wide range of structural materials on the market, different in chemical, physical and biological properties, and information about them is very often limited only by the manufacturer's instructions, which allows to determine, at best, only the scope. In this regard, there are difficulties in choosing the optimal material for this particular situation, since without a thorough approach to studying the properties of the main materials used in dentistry, it seems difficult to provide high-quality dental care, the result of which is functional usefulness, aesthetics and durability.The problem of an individual approach to the choice of structural material from the standpoint of personalized medicine is even less studied - there are no data in the literature on the role of normal and pathogenic microflora in the development of destructive changes in structures and the development of complications, taking into account a personalized approach when analyzing the composition of the microbiota of the oral cavity, biochemical parameters of the oral fluid, blood depending on the material from which the structure is made.",[29],[195],"microbiota","2024-12-31",{"date":198,"type":45},"2025-01-01",{"date":200,"type":45},"2023-06-01",{"date":202,"type":21},"2025-04-01",{"name":204,"class":52},"Samara State Medical University"]